SRSheikh Tamir Rashid

Sheikh Tamir Rashid

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sheikh Tamir Rashid has a total of 320 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Precision Gene-Based Therapy for Progressive Familial Intrahepatic Cholestasis: Matching Platform to Disease Biology

    by Ziyu Jiang, S. Tamir Rashid, Paul Gissen, Claudiu A. Cozmescu

    Progressive familial intrahepatic cholestasis (PFIC) encompasses genetically heterogeneous disorders affecting bile transport, membrane organisation, epithelial polarity and bile-acid signalling. Current medical and surgical treatments can improve symptoms and disease course in selected patients, but substantial unmet need remains, particularly in severe early-onset disease and multisystem disorders. This review considers the thirteen numbered PFIC subtypes and selected related monogenic cholestatic conditions, relating their mechanisms to gene addition, genome editing, splice correction, messenger RNA replacement and cell-based strategies. Published PFIC intervention evidence is predominantly preclinical, with proof of concept in selected mouse models and in vitro systems. Clinical experience in other liver diseases provides relevant delivery and safety precedents but does not establish efficacy in PFIC. Platform selection will depend on molecular mechanism, target tissue, therapeutic threshold, disease stage and the durability required during liver growth. Severe disease identifies unmet need rather than a proven optimal platform. We propose a framework for research prioritisation and identify the studies needed to establish sustained benefit, genomic and immunological safety, and clinically meaningful outcomes.

  • Open Access

    Precision Gene-Based Therapy for PFIC: Matching Platform to Disease Biology

    by Ziyu Jiang, S. Tamir Rashid, Paul Gissen, Claudiu A. Cozmescu

    Progressive familial intrahepatic cholestasis (PFIC) encompasses genetically heterogeneous disorders affecting bile transport, membrane organisation, epithelial polarity and bile-acid signalling. Current medical and surgical treatments can improve symptoms and disease course in selected patients, but substantial unmet need remains, particularly in severe early-onset disease and multisystem disorders. This review considers the thirteen numbered PFIC subtypes and selected related monogenic cholestatic conditions, relating their mechanisms to gene addition, genome editing, splice correction, messenger RNA replacement and cell-based strategies. Published PFIC intervention evidence is predominantly preclinical, with proof of concept in selected mouse models and in vitro systems. Clinical experience in other liver diseases provides relevant delivery and safety precedents but does not establish efficacy in PFIC. Platform selection will depend on molecular mechanism, target tissue, therapeutic threshold, disease stage and the durability required during liver growth. Severe disease identifies unmet need rather than a proven optimal platform. We propose a framework for research prioritisation and identify the studies needed to establish sustained benefit, genomic and immunological safety, and clinically meaningful outcomes.

  • Open Access

    Prevalence of liver disease and liver transplantation in pediatric ZZ alpha-1 antitrypsin deficiency: A systematic review and meta-analysis

    by Adam M. Syanda, Dimitra Georgantaki, Muhammad Awsaf, Manako Sakai, Richard Thompson, Mariam Molokhia, Nedim Hadžić, S. Tamir Rashid


  • Open Access

    Liver Disease and Prevalence of Liver Transplantation in Adults With ZZ Alpha‐1 Antitrypsin Deficiency—A Meta‐Analysis

    by Adam M. Syanda, Dimitra Georgantaki, Muhammad Awsaf, Mariam Molokhia, S. Tamir Rashid

    Alpha‐1 antitrypsin deficiency (A1ATD) is an inherited metabolic disorder caused by a mutation (ZZ) in the SERPINA1 gene. Carriers are predisposed to liver and lung pathology. The severity of A1ATD‐associated liver disease is highly variable, necessitating further characterisation. This study aims to investigate the risk and extent of liver disease and the prevalence of liver transplantation in ZZ A1ATD patients. Several established databases, including Ovid, EBSCO, PubMed, and Cochrane Library, were searched from inception to May 12, 2024. Data were pooled using a random effects model, and study weight was calculated using the inverse variance method. Crude odds ratios (cOR) were calculated using participants with the MM genotype as the comparator. The study was registered in PROSPERO (CRD42022335666). Of the 4420 studies identified, 45 studies and 8638 A1ATD patients (38.8% female) were included. ZZ A1ATD patients demonstrate an increased risk of liver diseases compared to controls, including steatosis (crude odds ratio (cOR): 1.52 [95% CI: 1.21, 1.91]), fibrosis (cOR: 9.85 [95% CI: 5.70, 17.03]), cirrhosis (cOR: 10.43 [95% CI: 5.51, 19.73]), and liver cancers (cOR: 14.12 [95% CI: 6.50, 30.66]). The prevalence of liver transplantation is considerable, with rates reaching 5% [95% CI: 0.00, 12.34]. Our findings confirm the substantial burden of liver disease in ZZ A1ATD patients, including subclinical manifestations such as steatosis and fibrosis that may remain undetected. Given the lack of approved treatments for A1ATD‐associated liver disease, prioritising the development of novel therapies to stop or reverse liver disease is essential.


  • Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors

    by Deniz Kent, Soon Seng Ng, Adam M. Syanda, Payam Khoshkenar, Riccardo Ronzoni, Chao Zheng Li, Marina Zieger, Cindy Greer, Stephanie Hatch, Joe Segal, et al.

    Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1 ‘Z’ genetic variant (PiZ) driving AAT protein misfolding in hepatocytes. There remain no approved medicines for this disease. Here, we report the results of a small molecule screen performed in patient derived iPSC-hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2) as a potentially new therapeutic target. Of the commercially available LRRK2 inhibitors tested, we identified CZC-25146, a candidate with favorable pharmacokinetic properties, as being capable of reducing polymer load, increasing normal AAT secretion, and reducing inflammatory cytokines in both cells and PiZ mice. Mechanistically, this effect was achieved through induction of autophagy. Our findings support the use of CZC-25146 and LRRK2 inhibitors in hepatic proteinopathy research and their further investigation as novel therapeutic candidates for A1ATD. Export


  • Open Access

    RGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling

    by Samuel J.I. Blackford, Tracy T.L. Yu, Michael D.A. Norman, Adam M. Syanda, Michail Manolakakis, Dariusz Lachowski, Ziqian Yan, Yunzhe Guo, Elena Garitta, Federica Riccio, et al.


  • Open Access

    Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice

    by Helen A. B. Paterson, Sijia Yu, Natalia Artigas, Miguel A. Prado, Nejc Haberman, Yi-Fang Wang, Andrew M. Jobbins, Elena Pahita, Joao Mokochinski, Zoe Hall, et al.

    RNA alternative splicing (AS) expands the regulatory potential of eukaryotic genomes. The mechanisms regulating liver-specific AS profiles and their contribution to liver function are poorly understood. Here, we identify a key role for the splicing factor RNA-binding Fox protein 2 (RBFOX2) in maintaining cholesterol homeostasis in a lipogenic environment in the liver. Using enhanced individual-nucleotide-resolution ultra-violet cross-linking and immunoprecipitation, we identify physiologically relevant targets of RBFOX2 in mouse liver, including the scavenger receptor class B type I (Scarb1). RBFOX2 function is decreased in the liver in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis. Our findings demonstrate that specific AS programmes actively maintain liver physiology, and underlie the lipotoxic effects of obesogenic diets when dysregulated. Splice-switching oligonucleotides targeting this network alleviate obesity-induced inflammation in the liver and promote an anti-atherogenic lipoprotein profile in the blood, underscoring the potential of isoform-specific RNA therapeutics for treating metabolism-associated diseases.


  • Open Access

    Small molecule screen employing patient-derived iPSC hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency

    by Deniz Kent, Soon Seng Ng, Payam Khoshkenar, Adam Syanda, Chao Zheng Li, Marina Zieger, Stephanie Hatch, Joe Segal, Samuel Blackford, Kaixing Le, et al.

    Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1-Z genetic variant (PiZ) leading to protein misfolding and liver toxicity. There remain no approved medicines for this disease. Here we report the results of a small molecule screen performed in patient-derived iPSC hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2), as a potentially new therapeutic target. Genetic deletion of LRRK2 in PiZ mice reduced both intrahepatic misfolded polymers and fibrosis leading us to test a library of commercially available LRRK2 inhibitors across several cell models. One of these molecules, CZC-25146, a candidate with favourable pharmacokinetic properties, reduced polymer load, increased normal AAT secretion and reduced inflammatory cytokines in both cells and the PiZ mouse. Mechanistically, this effect was achieved via inhibition of LRRK2 kinase activity and autophagy induction. These findings support the use of CZC-25146 (and potentially LRRK2 inhibitors more broadly) in hepatic proteinopathy disease research and as potential new therapies.

  • Open Access

    Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency

    by Chao Zheng Li, Hiromi Ogawa, Soon Seng Ng, Xindi Chen, Eriko Kishimoto, Kokoro Sakabe, Aiko Fukami, Yueh-Chiang Hu, Christopher N. Mayhew, Jennifer Hellmann, et al.


  • Open Access

    Small molecule screen employing patient-derived iPS hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency

    by Deniz Kent, Soon Seng Ng, Payam Khoshkenar, Adam M. Syanda, Chao Zheng Li, Marina Zieger, Cindy Greer, Stephanie B Hatch, Joe M Segal, Samuel J.I. Blackford, et al.

    Alpha-1 antitrypsin deficiency is a life-threatening condition caused by inheritance of the SERPINA1 gene ‘Z’ variant. This single base pair mutation leads to protein misfolding, ER entrapment and gain of toxic function. Despite the significant unmet medical need presented by this disorder, there remain no approved medicines and the only curative option is liver transplantation. We hypothesized that an unbiased screen of human hepatocytes harbouring the Z mutation (ATZ) using small molecules targeted against protein degradation pathways would uncover novel biological insights of therapeutic relevance. Here we report the results of that screen performed in a patient-derived iPSC model of ATZ. Starting from 1,041 compounds we identified 14 targets capable of reducing polymer burden, including Leucine-rich repeat kinase-2 (LRRK2), a well-studied target in Parkinson’s. Genetic deletion of LRRK2 in ATZ mice reduced polymers and associated fibrotic liver disease leading us to test a library of commercially available LRRK2 kinase inhibitors in both patient iPSC and CHO cell models. One of the molecules tested, CZC-25146, reduced polymer load, increased normal AAT secretion and reduced inflammatory cytokines with pharmacokinetic properties supporting its potential use for treating liver diseases. We therefore tested CZC-25146 in the ATZ mouse model and confirmed its efficacy for polymer reduction without signs of toxicity. Mechanistically, in both human and mouse models, our data show CZC-25146 inhibits LRRK2 kinase activity and induces autophagy. Cumulatively, these findings support the use of CZC-25146 and LRRK2 inhibitors in general in hepatic proteopathy disease research and as potential new treatment approaches for patients. One Sentence Summary: A small molecule screen in patient iPSCs with in vivo validation in mice identifies LRRK2 as a new therapeutic target for Alpha-1 Antitrypsin Deficiency.